The No Moni study

Absence of neuromuscular monitoring during anesthesia and extubation: what sugammadex dose is appropiate to guarantee a TOF-ratio of 1? A pharmacometric analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20049

Enrollment

Registered

2019-01-09

Start date

2018-09-04

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Residual Neuromuscular Block Sugammadex

Interventions

None

Eligibility

Inclusion criteria

Inclusion criteria: ->18 years -American Society of Anesthesiologists physical status I-III -Scheduled to undergo general anesthesia with the use of a neuromuscular blocking agent for elective surgery

Exclusion criteria

Exclusion criteria: -Neuromuscular disease -Diabetes mellitus -Obesity defined as a BMI >30 -Indication for a rapid sequence induction, -Expected difficult intubation or ventilation -Chronic kidney failure (EGFR <30), liver failure, pregnancy and allergy to neuromuscular blocking agent (rocuronium) or to the reversal agent (sugammadex).

Design outcomes

Primary

Measure	Time frame
Time to complete recovery of neuromuscular function after sugammadex administration.	—

Contacts

Public ContactMaarten Honing

LUMC

g.h.m.honing@lumc.nl0715264038

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)